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The existence of a sex difference in Parkinson’s disease (PD) is observed as related to
several variables, including susceptibility of the disease, age at onset, and symptoms.
These differences between men and women represent a signiﬁcant characteristic of PD,
which suggest that estrogens may exert beneﬁcial effects against the development and
the progression of the disease. This paper reviews the neuroprotective and neuromodula-
tor effects of 17β-estradiol and progesterone as compared to androgens in the nigrostriatal
dopaminergic (NSDA) system of both female and male rodents. The 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) mice model of PD and methamphetamine toxicity faith-
fully reproduce the sex differences of PD in that endogenous estrogen levels appear to
inﬂuence the vulnerability to toxins targeting the NSDA system. Exogenous 17β-estradiol
and/or progesterone treatments show neuroprotective properties against NSDA toxins
while androgens fail to induce any beneﬁcial effect. Sex steroid treatments show male
and female differences in their neuroprotective action against methamphetamine toxicity.
NSDA structure and function, as well as the distribution of estrogen receptors, show sex
differences and may inﬂuence the susceptibility to the toxins and the response to sex
steroids. Genomic and non-genomic actions of 17β-estradiol converge to promote survival
factors and the presence of both estrogen receptors α and β are critical to 17β-estradiol
neuroprotective action against MPTP toxicity.
Keywords: 17β-estradiol, androgens, dopamine, neuroprotection, neuromodulation, sex difference,MPTP,metham-
phetamine
PARKINSON’S DISEASE
SEX DIFFERENCES
Parkinson’s disease (PD) is a neurodegenerative disorder char-
acterized by a progressive and selective loss of dopamine (DA)
cell bodies in substantia nigra (Dauer and Przedborski, 2003).
The death of nigral DA neurons results in striatal DA decrease,
leading to a dysfunction in basal ganglia process, and the appear-
ance of clinical symptoms such as resting tremor, rigidity, and
bradykinesia (Obeso et al., 2008).
Several variables (including susceptibility to the disease, age at
onset, symptoms) support the existence of a sex difference in PD
(Miller and Cronin-Golomb, 2010). While most studies report a
higher predisposition of PD in men (Van Den Eeden et al., 2003;
Wooten et al., 2004; Shulman, 2007), sex is not considered a risk
factor in a few studies (Granieri et al., 1991; de Rijk et al., 1995).
Men have at least a 1.5-fold greater risk than women of developing
PD (Van Den Eeden et al., 2003; Wooten et al., 2004). The age at
onset in women occurs about 2 years later compared to men in
the majority of studies (Twelves et al., 2003; Haaxma et al., 2007),
while no difference has also been reported in one study (Baba
et al., 2005). Moreover, differences in the proﬁle of motor symp-
toms between men and women have also been reported. Total
motor scores on the modiﬁed uniﬁed Parkinson’s disease rating
scale (UPDRS) do not differ between men and women however,
men have more advanced rigidity and women present with greater
instability scores (Baba et al., 2005). When UPDRS motor scores
were examined as a function of disease progression, sex differ-
ences were not observed in early PD (less than 5 years duration)
however, women have better motor scores than men in advanced
PD (disease duration more than 5 years; Lyons et al., 1998). Not
only do men exhibit more severe parkinsonian motor features
than women but a greater improvement of motor function fol-
lowing levodopa therapy is reported in women (Growdon et al.,
1998; Lyons et al., 1998; Zappia et al., 2005). Haaxma et al. (2007)
found that women have a higher frequency of presentation with
the tremor dominant form of PD, which has been associated with
a slower disease progression. [123I]FR-CIT single photon emis-
sion computed tomography (SPECT) measurements show that, at
symptom onset, women had superior levels of striatal DA binding
than men, suggesting that the development of symptomatic PD
may be delayed by higher physiological striatal DA levels (Haaxma
et al., 2007). In light of these ﬁndings, the authors suggested that
the phenotype of PD in women is more benign (Haaxma et al.,
2007). It should be noted however, that differences in disease pre-
sentation, for example, the initial symptom of tremor in women,
was not consistently reported (Baba et al., 2005). Thus, sex differ-
ences represent a notable characteristic of PD, which suggests that
estrogens may exert beneﬁcial effects against the development and
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progression of the disease in women and/or that androgens may
exert destructive effects upon the development and progression of
the disease in men.
INFLUENCE OF ENDOGENOUS AND EXOGENOUS ESTROGENS
Several studies have been conducted to investigate how endoge-
nous estrogen status and estrogen therapy inﬂuence the risk of
PD. A longer fertile lifespan (difference between age at menarche
and age at menopause) was associated with a decreased risk of PD
in women with natural menopause (>39 years of fertile lifespan)
compared to the lowest fertile lifespan (<33 years) as reported
among 83,482 women participating in the Observational Study
of the Women’s Health Initiative (WHI-OS; Saunders-Pullman
et al., 2009). A fertile lifespan shorter than 36 years was associ-
ated with an increased risk of PD and an earlier menopause was
more common among women with PD (Ragonese et al., 2004). A
case–control study reported that women with PD had undergone
hysterectomy (with or without unilateral oophorectomy) more
frequently than control subjects (Benedetti et al., 2001), how-
ever data from another report indicated that surgical menopause
was associated with a decreased incidence of PD (Ragonese et al.,
2004). Most ﬁndings suggest a beneﬁcial effect of estrogen with
regard to PD risk as the use of either postmenopausal estrogen
(Currie et al., 2004; Popat et al., 2005) or oral contraceptives
(Ascherio et al., 2003; Simon et al., 2009) were associated with
a reduced risk of PD, and women with PD were less likely to use
estrogen therapy (Benedetti et al., 2001); though there are also
data relating that a similar risk exists between women who have
or have not used estrogen therapy (Ascherio et al., 2003). The
use of estrogen therapy on the risk of PD varies depending on
the type of menopause, with increased risk in women with hys-
terectomy (Popat et al., 2005; Saunders-Pullman et al., 2009) and
decreased risk in women with natural menopause (Popat et al.,
2005). No association between exogenous or endogenous estro-
gens exposure on risk of PD has also been reported (Simon et al.,
2009).
In women with PD experiencing regular menstrual cycles a
worsening of parkinsonian symptoms was associated with pre-
menstrual and menstrual periods, when estrogens and proges-
terone are at a low level (Quinn and Marsden, 1986; Kompoliti
et al., 2000; Tolson et al., 2002). A reduction in levodopa effec-
tiveness was also observed before and during the menstruation
period in young PD women (Quinn and Marsden, 1986; Giladi
and Honigman, 1995). Although it was thought that estrogen was
the basis for these symptom ﬂuctuations, a study conducted in
a 5-week period in 10 PD women with menstrual cycles found
that serum estrogens and progesterone levels were not related to
PD severity (Kompoliti et al., 2000). Nevertheless, Horstink et al.
(2003) report ﬂuctuations of dyskinesias, a motor complication
induced by levodopa treatment, as associated with estradiol lev-
els in a young PD woman, with an increase in dyskinesia when
estradiol levels were highest, followed by a diminution of dyskine-
sia and a worsening of parkinsonism in the premenstrual period.
The majority of women with PD report a worsening of parkinson-
ian symptoms during pregnancy and into the postpartum period,
while some women do not experience any deterioration of their
symptoms (Golbe, 1987; Hagell et al., 1998; Shulman et al., 2000;
Robottom et al., 2008). Case reports have documented an increase
in total and motor UPDRS scores during and after pregnancy
(Shulmanet al.,2000),with a faster symptomprogression than that
observed in the comparison cohort (Robottom et al., 2008). The
substantial variations in estrogen levels during and after pregnancy
were proposed to be implicated in the worsening of parkinsonian
symptoms during these periods (Rubin, 2007; Robottom et al.,
2008).
An amelioration of PD symptoms and dyskinesia was reported
to be present under conditions of estrogen therapy or high levels of
endogenous estrogens (Villeneuve et al., 1978; Session et al., 1994;
Giladi and Honigman, 1995). Postmenopausal women with early
PD using estrogen therapy prior to initiation of levodopa have
lower symptom severity scores (Saunders-Pullman et al., 1999) but
estrogen therapy had no effect at later stages of the disease (Strijks
et al., 1999). Results from double-blind studies reported a reduc-
tion of the dose of levodopa required to improve motor function
in women receiving 17β-estradiol (Blanchet et al., 1999) and an
improvement of motor disability in PD women with motor ﬂuc-
tuations when treated with estrogens (Tsang et al., 2000) whereas
no effect of estrogen on motor function was also observed (Strijks
et al., 1999).
While in some cases conﬂicting information is reported from
the above human studies, a longer fertile lifespan seems to be con-
sistently associated with a decreased risk of PD, suggesting that
longer exposure to endogenous ovarian steroids exerts a beneﬁ-
cial effect against PD. PD symptoms seem to be modulated by
endogenous variation of steroids as reported by the majority of
women experiencing menstrual cycles and pregnancy. The most
conﬂicting data comes from the use of estrogen therapy (most
of the studies support a beneﬁcial effect of estrogens) but many
factors could inﬂuence the conclusion of these studies. First, a
variety of hormonal therapy compounds are available and the
studies do not always state the speciﬁc molecule used by women.
Further, the dose, timing of initiation of treatment and duration
of estrogen therapy can vary substantially. In addition, estrogen
therapy could be used alone or in combination with progestin
and the type of hormone therapy prescribed could differ between
women with a hysterectomy and women with natural menopause.
Indeed, women within the same cohort could have used differ-
ent preparations and doses of estrogen therapy and could have
experienced a different duration of treatment. Taken together, the
results from these studies suggest that exposure to endogenous and
exogenous estrogens seem to inﬂuence the risk and symptoms of
PD while further research concerning the exact regimen of hor-
monal therapy will require careful analyses to enable a deﬁnitive
conclusion.
ESTROGENS RECEPTOR, STEROIDS, AND PARKINSON’S DISEASE
Estrogens receptor (ER) α and ERβ polymorphism were found
to be unrelated with an increased risk of PD (Maraganore et al.,
2002; Westberg et al., 2004; Li et al., 2009). Alternatively, ERβ
polymorphism is reported more frequently in PD patients with
an early age at onset (Westberg et al., 2004; Hakansson et al.,
2005). A small number of studies have investigated alterations of
neurosteroid synthesis in PD. Reduced levels of allopregnanolone
and 5α-dehydroprogesterone were found in the cerebrospinal
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ﬂuid of PD patients (di Michele et al., 2003). In the substan-
tia nigra, reductions of 5α-reductase protein and mRNA were
observed (Luchetti et al., 2010), which could lead to decreased
synthesis of 5α-dehydroprogesterone and subsequently allopreg-
nanolone (di Michele et al., 2003). Expression of sulfotransferase
2B1, an enzyme catalyzing the conversion of pregnenolone and
dehydroepiandrosterone into their sulfated esters, in the substan-
tia nigra was also downregulated and in the caudate nucleus,
expression of 3α-hydroxysteroid dehydrogenase type 3, an enzyme
catalyzing the synthesis of allopregnanolone, was upregulated
(Luchetti et al., 2010), suggesting a compensatory mechanism in
response to the loss of input from the substantia nigra. The authors
suggest an involvement of neurosteroids in the neurodegenerative
process of PD (Luchetti et al., 2010).
INFLUENCE OF SEX STEROIDS IN EXPERIMENTAL MODELS
OF PARKINSON’S DISEASE
SEX DIFFERENCES AND INFLUENCE OF ENDOGENOUS HORMONES
Two animal models of induced degeneration affecting the nigros-
triatal dopaminergic (NSDA) system are reviewed here as related
to the inﬂuence of sex steroids – the 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) model of PD and methamphetamine
(MA)-induced DA toxicity. While both agents primarily target
the NSDA system, they differ with regard to their mechanisms of
action. For MPTP, conversion to its active metabolite, 1-methyl-
4-phenylpyridinium (MPP+), is required followed by uptake into
the DA neuron via the DA transporter (DAT). The interaction
of MPP+ with mitochondrial complex 1 results in a disruption
of the respiratory chain and eventual cell destruction. The exact
mechanisms for toxicity resulting from MA remain elusive, but it
is believed to produce a reversal in DAT function thus producing
excessive amounts of DA which have the potential of generating
free radicals and oxidative stress. Studies in these animal models
have shown a greater neurotoxic effect in male than female mice,
as observed by more extensive striatal DA reduction and a greater
decrease in DAT speciﬁc binding in striatum (Wagner et al., 1993;
Dluzen et al., 1996;Miller et al., 1998;Yu and Liao, 2000b; Bourque
et al., 2009, 2011). Moreover, the levels of endogenous sex steroids
have been reported to affect the susceptibility of female mice to the
toxin. In female BALB/c mice treated with MA, a greater DA deple-
tion was observed when the toxin was administered at diestrus
(when estrogens levels are low) whereas lower DA loss occurs at
proestrus (when estrogens levels are high; Yu and Liao, 2000b).
This effect of estrous cycle variation seems to be strain depen-
dent since this difference in MA sensibility was not observed in
the C57BL/6J strain of mice (Yu and Liao, 2000b). These ani-
mal models faithfully reproduce the sex differences of PD in that
endogenous estrogen levels appear to inﬂuence the vulnerability
to toxins targeting the NSDA system and support a beneﬁcial role
of estrogens against NSDA neurodegeneration.
EFFECTS OF ESTROGENS AND PROGESTERONE IN FEMALE AND MALE
RODENTS
Experimental studies have been conducted in order to investi-
gate the potential beneﬁcial effect of exogenous sex steroid treat-
ments against NSDA toxins. A summary of these studies showing
steroids, dose, toxin, and DA markers investigated is listed in
Tables 1–4. These studies are separated by sex to highlight the
observed sex differences and we refer the reader to the tables for
details and a complete reference to relevant studies. Beneﬁcial
effects of 17β-estradiol and estradiol benzoate on DA concen-
trations against MPTP toxicity in female and male mice (intact or
gonadectomized) are shown when physiological concentrations of
this gonadal steroid are administered prior to the toxin (Tables 1
and 3; Dluzen et al., 2001b; D’Astous et al., 2004b; Liu et al., 2008).
A protective effect of 17β-estradiol or estradiol benzoate against
MA-induced DA loss was also obtained with a pre-treatment in
female mice (Dluzen et al., 2002; D’Astous et al., 2005a). In con-
trast, 17β-estradiol failed to show any protective effect on DA
content in gonadectomized male mice treated with MA (Ander-
son et al., 2005) and produced a severe acute toxicity to MA in
intact male mice (Dluzen et al., 2002). Timing of treatment with
17β-estradiol or estradiol benzoate seems to be critical to reach a
maximal beneﬁcial effect, with at least 24 h required for the pre-
treatment whereas shorter time intervals fail to achieve optimal
protection (Gajjar et al., 2003). In support of this ﬁnding are data
showing that treatment with a high dose of 17β-estradiol shortly
prior to and after MPTP injection failed to protect striatal DA
depletion whereas some effects were observed on DAT and tyro-
sine hydroxylase proteins levels (Ookubo et al., 2008). Moreover,
in a study investigating several markers of dopaminergic function,
the time required to obtain maximal protection against MA toxi-
city was observed with a 24-h pre-treatment of estradiol benzoate
while pre-treatments of 30min or 12 h showed incomplete and
varying degrees of neuroprotection (Gajjar et al., 2003), suggesting
different mechanisms of estradiol action (D’Astous et al., 2004a).
Since estradiol is a neuromodulator of DA metabolism (Sanchez
et al., 2010), investigations of the integrity of DA neurons using
other DA markers to demonstrate the beneﬁcial effect of estradiol
are critical. The DAT and the vesicular monoamine transporter 2
(VMAT2) are both important modulators of DA neurotransmis-
sion (Sotnikova et al., 2006;Guillot andMiller, 2009) andboth play
a pivotal role in MPTP and MA toxicities (Gainetdinov et al., 1997,
1998; Fumagalli et al., 1998, 1999). A decrease in DAT andVMAT2
binding in DA neurons of the PD brain is associated with the loss
of DA (Wilson et al., 1996). The protective effect of 17β-estradiol
on DA content observed in MPTP and MA mice has also been
shown on DAT and VMAT2 speciﬁc binding (Callier et al., 2001;
D’Astous et al., 2004a, 2005a; Jourdain et al., 2005).Moreover, pos-
itive correlations exist between DA concentrations and DAT and
VMAT2 levels, suggesting that binding to the transporters reﬂects
the degree of degeneration or protection (Jourdain et al., 2005).
While it has received less attention than 17β-estradiol, the
neuroprotective effect of the other major ovarian steroid prog-
esterone has also been investigated in animal models of PD. Like
17β-estradiol, progesterone shows beneﬁcial effects against MPTP
and MA toxicities (Grandbois et al., 2000; Yu and Liao, 2000a;
Callier et al., 2001; Yu et al., 2002; Morissette et al., 2008). In
contrast to 17β-estradiol, progesterone is neuroprotective in male
mice treated with MA (Yu et al., 2002). Sex differences in the
dose of progesterone used to be effective as a neuroprotectant
againstMAare also reported,withmalemice requiring lower doses
than females (Yu et al., 2002). Interestingly, co-administration
of 17β-estradiol and progesterone (Morissette et al., 2008), or
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Table 1 | In vivo studies and neuroprotection in female rodents: studies showing protection of DA markers.
Steroid Toxin Species Assay References
ESTROGENS
17β-estradiol
0.5 or 2mg/kg 30min before and
90min after MPTP
MPTP Intact mice DOPAC concentrations (with
2mg/kg)
Ookubo et al. (2008)
DAT (with 2mg/kg) andTH
protein levels
Pellet (0.1mg, 60-day release) for
15 days
MPTP OVX mice DA concentrations Dluzen et al. (1996)
Pellet (0.1mg, 21-day release) for
14 days
MPTP OVX mice DA concentrations Dluzen et al. (2001b)
Pellet (235μg/ml) before MPTP and
2days after
MPTP OVX mice DA, DOPAC, and HVA
concentrations
Miller et al. (1998)
50μg/kg for 19 days MPTP OVX mice DAT mRNA levels Liu et al. (2004)
Single injection of 10μg,
co-administered with MPP+
MPP+ Intact rats DA concentrations
TH immunoreactivity
Tomas-Camardiel et al. (2002)
Pellet (0.1mg, 21-day release) for
14 days
MA Intact and OVX mice DA concentrations Dluzen et al. (2001a, 2002),
Gao and Dluzen (2001b)
Estradiol benzoate
50μg/kg for 8 days MPTP OVX mice DA, DOPAC, and HVA
concentrations
Liu et al. (2008)
TH immunoreactivity
DAT andTH mRNA levels
48 pg or 0.47μg for 3 days MA OVX mice (6weeks) DA concentrations Yu and Liao (2000a), Yu et al.
(2002)
1, 10, or 40μg 24h before MA MA OVX mice DA concentrations
DAT and VMAT2 speciﬁc binding
Mickley and Dluzen (2004),
D’Astous et al. (2005a)
10μg 0.5, 12, or 24 h before MA MA OVX mice DA concentrations (at 12 and
24 h)
Gajjar et al. (2003), D’Astous
et al. (2004a)
DOPAC/DA ratio
DAT speciﬁc binding (at 24 h)
DAT mRNA levels
PROGESTERONE
0.467mg for 3 days MA OVX mice DA concentrations Yu and Liao (2000a)
17β-ESTRADIOL BENZOATE+PROGESTERONE
2days of estradiol benzoate treatment
(0.467μg) following by 1 day
progesterone treatment (0.467mg)
MA OVX mice DA and DOPAC concentrations Yu and Liao (2000a)
DOPAC, 3,4-dihydrophenylacetic acid; HVA, homovanillic acid; OVX, ovariectomized; TH, tyrosine hydroxylase.
administration of progesterone following 17β-estradiol treatment
(Yu and Liao, 2000a) does not oppose the beneﬁcial effect of 17β-
estradiol, as has been observed with medroxyprogesterone acetate
(Nilsen and Brinton, 2002).
17β-estradiol clearly shows a neuroprotective capacity when
administered as a pre-treatment, that is,under conditions of a non-
injured brain. Whether 17β-estradiol could retain this capacity
within an impaired dopaminergic system has also been investi-
gated. Estradiol treatment after a MA-induced lesion has been
introduced lacks a protective capacity against MA toxicity in
female mice (Gao and Dluzen, 2001b; Gajjar et al., 2003) and
could evenworsen the extent of observed damage (Liu andDluzen,
2006). This is, in part, consistent with the healthy cell bias of
estrogen’s effect, which proposes that if neurons are healthy at
the time of estrogen treatment, their response to estrogen is ben-
eﬁcial for both survival and neurological functions whereas in
the presence of impaired function, estrogen exposure over time
exacerbates brain injury (Chen et al., 2006; Brinton et al., 2008).
Accordingly, 17β-estradiol can prevent but does not seem to have
the capacity of regeneration nor is it protective under conditions
of an impaired system.
EFFECTS OF ANDROGENS IN FEMALE AND MALE RODENTS
Androgenic compounds have also received attention in order to
investigate their effect in neuroprotective studies. Steroids could
be synthesized in the brain, as supported by the presence and
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Table 2 | In vivo studies and neuroprotection in female rodents: studies showing no protection of DA markers.
Steroid Toxin Species Assay References
ESTROGENS
17β-estradiol
0.5 or 2mg/kg 30min before and
90min after MPTP
MPTP Intact mice DA, DOPAC (with 0.5mg/kg),
and HVA concentrations
Ookubo et al. (2008)
DAT protein levels (with
0.5mg/kg)
50μg/kg for 19 days MPTP OVX mice TH mRNA levels Liu et al. (2004)
Pellet (0.1mg, 21-day release) for
7 days (7 days after MA)
MA OVX mice DA concentrations Gao and Dluzen (2001b)
Estradiol benzoate
10μg, 1 injection 0.25, 0.5, 1, or 2 h
after MA
MA OVX mice DA concentrations,
DOPAC/DA ratio
Gajjar et al. (2003)
10μg, 1 injection at 1week post-MA MA OVX mice DA and DOPAC
concentrations
Liu and Dluzen (2006)
0.46μg for 3 days MA OVX mice (4weeks) DA and DOPAC
concentrations
Yu et al. (2002)
17α-estradiol
Pellet (0.1mg, 21-day release) for
14 days
MPTP OVX mice DA concentrations Dluzen et al. (2001b)
PROGESTERONE
0.47μg for 3 days MA OVX mice DA and DOPAC
concentrations
Yu et al. (2002)
ANDROGENS
Testosterone
10μg, 1 injection MPP+ Intact rats DA concentrations Tomas-Camardiel et al. (2002)
TH immunoreactivity
Pellet (5mg, 21-day release) for 14 days MA Intact and OVX mice DA concentrations Gao and Dluzen (2001a),
Dluzen et al. (2002)
0.005–50μg (1 injection), 24 h before
MA
MA Intact and OVX mice DA concentrations Lewis and Dluzen (2008)
DOPAC, 3,4-dihydrophenylacetic acid; HVA, homovanillic acid; OVX, ovariectomized; TH, tyrosine hydroxylase.
distribution of neurosteroidogenic enzymes (DoRego et al., 2009).
Thus, estradiol and testosterone could be formed in the brain.
Aromatase, the enzyme converting testosterone to estradiol and
androstenedione to estrone, and 5α-reductase, the enzyme con-
verting testosterone into dihydrotestosterone, are present in the
brain (Do Rego et al., 2009). While testosterone is considered
an important precursor of estradiol biosynthesis and could also
be 5α-reduced into dihydrotestosterone (important in testis and
ovary), a direct effect of testosterone by itself is also possible as has
been described in intracrine tissues (Luu-The and Labrie, 2010).
As a result of such testosterone biotransformation it is oftentimes
not certainwhether anymodulatory effects upon toxicity from this
steroid result from testosterone, its metabolites and/or its possible
conversion into estradiol. To investigate speciﬁcally the androgenic
potential in neuroprotective activity, dihydrotestosterone, the
most potent androgen, is a more appropriate compound since
it is not aromatized.
In MPTP-treated male mice, testosterone treatment fails to
show any protective effect (Dluzen, 1996; Ekue et al., 2002), sug-
gesting that testosterone is not biotransformed into estradiol in the
brain,more speciﬁcally in the basal ganglia, in adequate concentra-
tions to reach protective levels. The lack of effect of testosterone is
not sex-dependent since this steroid does not protect against MA
toxicity in either female or male mice (Gao and Dluzen, 2001a;
Lewis and Dluzen, 2008). Not only does testosterone lack a neuro-
protective function but further exacerbates DA depletion in male
mice receiving a chronic (Dluzen et al., 2002) or acute (Lewis
and Dluzen, 2008) administration of testosterone. These ﬁndings
of an exacerbation of MA-induced DA toxicity with testosterone
are supported by data from the 6-hydroxydopamine rat model
which shows that greater amounts of striatal DA depletion are
obtained in intact versus gonadectomized male rats subjected to
6-hydroxydopamine (Murray et al., 2003; Gillies et al., 2004).
Dihydrotestosterone also lacks any beneﬁcial effect against loss
of striatal DA concentrations in MPTP-lesioned male mice (Ekue
et al., 2002), suggesting that stimulation of androgen receptors was
not effective in inducing a protective effect. Indeed, these studies
show that androgens do not play a protective role but may actu-
ally intensify toxicity in the NSDA pathway. Such effects may be
relatively speciﬁc to the NSDA system as testosterone is reported
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Table 3 | In vivo studies and neuroprotection in male rodents: studies showing protection of DA markers.
Steroid Toxin Species Assay References
ESTROGENS
17β-estradiol
1μg B.I.D. for 10 days MPTP Intact mice DA, DOPAC, and
HVA concentrations
DAT and VMAT2
speciﬁc binding DAT,
VMAT2, andTH
mRNA levels
Callier et al. (2000. 2001), Grandbois et al.
(2000), Ekue et al. (2002), D’Astous et al.
(2003, 2004b, 2005b, 2006), Morissette et al.
(2007), Al-Sweidi et al. (2011)
2μg B.I.D. for 10 days MPTP Intact mice DA, DOPAC, and
HVA concentrations
Jourdain et al. (2005)
DAT and VMAT2
speciﬁc binding
DAT, VMAT2, andTH
mRNA levels
1μg B.I.D. 1, 3, or 5 days before
MPTP and 5days after
MPTP Intact mice DA, DOPAC, and
HVA concentrations
Morissette et al. (2008)
1μg B.I.D. for 11 days MPTP Intact mice TH immunoreactivity Tripanichkul et al. (2006, 2010)
1μg B.I.D. for 11 days MPTP Intact mice DA concentrations Ramirez et al. (2003)
1μg B.I.D. for 5 days and until 2,
4, or 6 days after MPTP
MPTP Intact mice DA concentrations Ramirez et al. (2003)
0.5 or 2mg/kg 30min before and
90min after MPTP
MPTP Intact mice DOPAC
concentrations
Ookubo et al. (2008)
DAT (with 2mg/kg)
andTH protein levels
Pellet (0.1mg, 60-day release)
for 15 days
MPTP GDX mice DA concentrations Dluzen et al. (1996)
100μg daily for 9 or 16 days MPTP GDX mice TH immunoreactivity Shughrue (2004)
Estrone
2μg B.I.D. for 10 days MPTP Intact mice DAT speciﬁc binding Jourdain et al. (2005)
VMAT2 mRNA levels
PROGESTERONE
1μg B.I.D. for 10 days MPTP Intact mice DA and HVA
concentrations
Grandbois et al. (2000), Callier et al. (2001),
Morissette et al. (2008)
DAT speciﬁc binding
0.47μg for 3 days MA Intact mice DA and DOPAC
concentrations
Yu et al. (2002)
17β-estradiol+progesterone
1μg B.I.D. of both 17β-estradiol
and progesterone for 10 days
MPTP Intact mice DA concentrations Morissette et al. (2008)
B.I.D., twice a day; DOPAC, 3,4-dihydrophenylacetic acid; HVA, homovanillic acid; GDX, gonadectomized; TH, tyrosine hydroxylase.
to exert neuroprotective effects in others models (Bialek et al.,
2004).
COMPARISON BETWEEN CLINICAL AND ANIMAL REPORTS
There is a relatively good consistence between clinical and animal
data concerning the neuroprotective activity of ovarian steroids.
Longer exposure to ovarian steroids is associated with a reduce
risk of PD in women as presented in Section“Inﬂuence of Endoge-
nous and Exogenous Estrogens.” In animal models, pre-treatment
with both 17β-estradiol and progesterone shows neuroprotec-
tive activity against MPTP and MA, while 17β-estradiol lacks
neuroprotective effect when administered under condition of
impaired NSDA system (see Effects of Estrogens and Progesterone
in Female and Male Rodents).
While animal studies show that 17β-estradiol does not exert
any neuroprotective effect when administered after the lesion,
clinical reports suggest that estrogens can act as a neuro-
modulator of DA system on PD symptoms. Women with
PD experience worsening of their symptoms during periods
of low endogenous steroids exposure and estrogen therapy
has been reported to improve PD symptom (see Inﬂuence of
Endogenous and Exogenous Estrogens). To our knowledge no
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Table 4 | In vivo studies and neuroprotection in male rodents: studies showing no protection of DA markers.
Steroid Toxin Species Assay References
ESTROGENS
17β-estradiol
1μg B.I.D. for 10 days MPTP Intact mice DAT speciﬁc binding
(extensive lesion)
Callier et al. (2000)
12μg 0.75, 2, or 24 h before
MPTP
MPTP Intact mice DA concentrations Ramirez et al. (2003)
0.1, 0.32, or 3.2μg B.I.D. for
11 days
MPTP Intact mice DA concentrations Ramirez et al. (2003)
0.05 or 0.2mg/kg B.I.D. for
10 days
MPTP Intact mice DA, DOPAC, and HVA
concentrations
Ookubo et al. (2008)
0.5 or 2mg/kg 30min before and
90min after MPTP
MPTP Intact mice DA and HVA
concentrations
Ookubo et al. (2008)
DAT protein levels (with
0.5mg/kg)
Pellet (0.1mg, 21-day release) for
14 days
MA GDX mice DA concentrations Dluzen et al. (2001a, 2002), Gao and
Dluzen (2001a,b)
Pellet (0.1mg, 21-day release) for
7 days (7 days after MA)
MA GDX mice DA concentrations Gao and Dluzen (2001b)
Estradiol benzoate
0.47μg for 3 days MA GDX mice DA and DOPAC
concentrations
Yu et al. (2002)
10μg, 1 injection at 1week
post-MA
MA GDX mice DA concentrations Liu and Dluzen (2006)
17α-estradiol
1μg B.I.D. for 10 days MPTP Intact mice DA, DOPAC, and HVA
concentrations
Callier et al. (2000, 2001), Grandbois
et al. (2000), D’Astous et al. (2005b)
DAT speciﬁc binding
and mRNA levels
0.1, 0.3, 1, or 3.2μg B.I.D. for
11 days
MPTP Intact mice DA concentrations Ramirez et al. (2003)
12μg 0.75, 2, or 24 h before
MPTP
MPTP Intact mice DA concentrations Ramirez et al. (2003)
Estriol
2μg B.I.D. for 10 days MPTP Intact mice DA, DOPAC, and HVA
concentrations
Jourdain et al. (2005)
DAT and VMAT2
speciﬁc binding
DAT, VMAT2, andTH
mRNA levels
Estrone
2μg B.I.D. for 10 days MPTP Intact mice DA, DOPAC, and HVA
concentrations
Jourdain et al. (2005)
VMAT2 speciﬁc binding
DAT andTH mRNA
levels
0.05 or 0.2mg/kg B.I.D. for
10 days
MPTP Intact mice DA, DOPAC, and HVA
concentrations
Ookubo et al. (2008)
0.5 or 2mg/kg 30min before and
90min after MPTP
MPTP Intact mice DA, DOPAC, and HVA
concentrations
Ookubo et al. (2008)
DAT andTH protein
levels
(Continued)
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Table 4 | Continued
Steroid Toxin Species Assay References
PROGESTERONE
1μg B.I.D. for 10 days MPTP Intact mice DOPAC concentrations
DAT mRNA levels
Grandbois et al. (2000), Callier et al.
(2001)
0.47μg for 3 days MA GDX mice (4weeks) DA concentrations Yu et al. (2002)
ANDROGENS
Testosterone
50μg testosterone B.I.D. for
10 days
MPTP Intact mice DA, DOPAC, and HVA
concentrations
Ekue et al. (2002)
DAT and VMAT2
speciﬁc binding
DAT mRNA levels
Pellet (0.1mg, 21-day release) for
17 days
MPTP GDX mice DA and DOPAC
concentrations
Dluzen (1996)
Pellet (5mg, 21-day release) for
14 days
MA Intact and GDX mice DA concentrations Gao and Dluzen (2001a), Dluzen et al.
(2002)
0.005–50μg (1 injection), 24 h
before MA
MA Intact and GDX mice DA concentrations Lewis and Dluzen (2008)
Dihydrotestosterone
1 or 50μg B.I.D. for 10 days MPTP Intact mice DA, DOPAC, and HVA
concentrations
Ekue et al. (2002)
DAT and VMAT2
speciﬁc binding
DAT mRNA levels
B.I.D., twice a day; DOPAC, 3,4-dihydrophenylacetic acid; HVA, homovanillic acid; GDX, gonadectomized; TH, tyrosine hydroxylase.
study performed in MPTP-treated rodents has investigated the
effect of estrogen treatment on symptoms. In female ovariec-
tomized hemiparkinsonianMPTPmonkeyswhere clear PD symp-
toms are present we have shown that acutely 17β-estradiol and
dehydroepiandrosterone (DHEA, a neurosteroid and precursor
of 17β-estradiol) potentiate the motor response obtained with
a low dose of levodopa the most common treatment for PD
(Belanger et al., 2003, 2006). Moreover, after a long washout
of the acute treatments, a chronic 17β-estradiol treatment in
these hemiparkinsonian MPTP monkeys increased striatal DA
and metabolites concentrations in the intact and lesioned side
while the DAT was only increased in the intact side of these very
extensively denervated monkeys (Morissette and Di Paolo, 2009).
The prodopaminergic effects of estradiol within the NSDA system
were observed on DA release and metabolism, DA receptor, DAT,
tyrosine hydroxylase, and monoamine oxidase (Sanchez et al.,
2010).
MECHANISM OF ACTION OF ESTRADIOL IN FEMALE AND MALE
RODENTS
Dopaminergic system
Sex differences in brain structure and function may affect the
susceptibility to the toxins. Striatal DA concentration shows no
difference between females and males whereas the number of
tyrosine hydroxylase immunoreactive cells in the substantia nigra
pars compacta were observed to be higher in male rodents, with a
sex difference in the topographical distribution (McArthur et al.,
2007a; Gillies and McArthur, 2010). In female rats, nigrostriatal
DAneurotransmission seems to bemore regulated by autoreceptor
and transporter mechanisms (Walker et al., 2006). Moreover,
although DAT afﬁnity is observed to be the same in males and
females, in female rodents superior DA uptake and vesicular stor-
age is present (Morissette and Di Paolo, 1993b; Walker et al., 2000;
Bhatt andDluzen, 2005; Ji et al., 2007;Dluzen et al., 2008), suggest-
ing a greater functional activity of DAT and VMAT2 in females.
Further evidence demonstrating a sex difference in DAT function
has been indicated from data showing that DA responses to MA
infusion in the presence of the DAT inhibitor nomifensine were
not abolished in female striatal tissue whereas the response was
eliminated in males (Kunnathur et al., 2006). The DAT is consid-
ered a critical component of MPTP and MA toxicities since this
transporter is the predominant site by which MA and MPP+ enter
DA cells (Sotnikova et al., 2006). The importance of the DAT in
MA and MPTP toxicities has been revealed in DAT knockout mice
that show no striatal DA neurotoxicity when treated with MA or
MPTP (Gainetdinov et al., 1997; Fumagalli et al., 1998), thus sub-
stantiating that decreased DAT activity is beneﬁcial against toxins.
This ﬁnding may seem inconsistent with the decreased suscep-
tibility of female mice to the toxins and the greater efﬁciency
of their DAT activity. In contrast to the effects resulting from a
decreased number DAT, that is, a reduced potential for uptake
of neurotoxins, a decreased number of VMAT2, has the potential
for increasing toxicity responses to MA and MPTP (Gainetdinov
et al., 1998; Fumagalli et al., 1999; Guillot et al., 2008). With fewer
Frontiers in Endocrinology | Neuroendocrine Science September 2011 | Volume 2 | Article 35 | 8
Bourque et al. Sex steroids neuroprotection and neuromodulation
VMAT2, there would be increased amounts of MPP+ available
to interact with mitochondrial complex 1, as less sequestering of
MPP+would occur (Guillot and Miller, 2009). Similarly, the high
amount of extra- and intra-cellular DA release by MA favors the
production of reactive species (Fleckenstein et al., 2007) which
could be sequestered by the VMAT2. Thus, a more efﬁcient DA
uptake as well as sequestering of excessive DA and MPP+ into
vesicular storage via the VMAT2, as reported in females, could
decrease the degree of oxidative stress and favor a more efﬁcient
protection of DA terminals when exposed to toxins that utilize
these transporters (Guillot and Miller, 2009).
Aromatase activity and mRNA expression show no sex differ-
ence in the mouse striatum (Kuppers and Beyer, 1998). However,
a sex difference in the expression and activity of aromatase is
reported in astrocytes, suggesting that astrocytes of females pos-
sess the potential to produce more estradiol than astrocytes of
males (Liu et al., 2007). Moreover, aromatase expression in astro-
cytes is induced following lesion and this aromatase activity has
been shown to be neuroprotective (Garcia-Segura, 2008). Male
rats treated with an aromatase inhibitor show increased suscep-
tibility to a dopaminergic toxin (McArthur et al., 2007b). In
addition, increased vulnerability to MPTP has been reported in
aromatase knockout female mice as compared to ovariectomized
wild-type females, indicating the contribution of extra-gonadal
17β-estradiol synthesis in the neuroprotection of the NSDA path-
way (Morale et al., 2008). The induction of aromatase expression,
and its neuroprotective effect, following lesion seem contradic-
tory with the increase toxicity in femalemice when 17β-estradiol is
given after MA and the lack of protective effect when 17β-estradiol
is given shortly after toxins. It should be noted that increased aro-
matase expression seems to be localized close to the lesion site
(Carswell et al., 2005), promoting local synthesis of estradiol, as
compared to systemic administration of 17β-estradiol given after
toxins. Furthermore, the “amount/degree” of the initial lesion
seems to be critical since the capacity for estrogen to enhance
the neurotoxicity response in the previously lesioned MA-treated
mice was more prominent under conditions where less initial
damage was present (Liu and Dluzen, 2006). In addition, the tim-
ing/duration of the initial lesion could also inﬂuence the effect of
estrogen on neurotoxicity.
The ﬁnding that estradiol protects DAT speciﬁc binding in
MPTP- and MA-treated mice could also be considered contra-
dictory since increased susceptibility to toxins is associated with
higher DAT levels. Inconsistencies in the literature have been
reported concerning the effect of estradiol treatment on DAT. Our
group reported that 17β-estradiol treatment in ovariectomized
female rats left the afﬁnity of [3H]GBR 12935 binding unchanged
whereas DAT density increased (Morissette and Di Paolo, 1993a).
A study using [3H]WIN35,428 has also reported unchanged afﬁn-
ity for DAT binding by 17β-estradiol treatment in the striatum of
gonadectomized male rats (Meyers and Kritzer, 2009). In contrast,
decreased DA uptake in ovariectomized female rats treated with
17β-estradiol has been reported using [3H]DA and a decrease of
DAT density measured by [3H]BTCP binding (Attali et al., 1997).
[3H]DA uptake from striatal synaptosomes of ovariectomized rats
was also shown to be dose-dependently inhibited by 17β-estradiol
(Disshon et al., 1998). While the issue regarding these effects of
estrogen upon the DAT remains controversial, a more consistent
result that emerges from studies of several laboratories is that 17β-
estradiol treatment of ovariectomized rats restores DA uptake and
DAT density to levels observed in intact female rats. Ovariec-
tomized female rats treated with 17β-estradiol have equivalent
DA uptake and DAT density as that of intact females not treated
with 17β-estradiol (Attali et al., 1997; Le Saux and Di Paolo, 2006;
McArthur et al., 2007b). Considering that females have a superior
function of DAT and VMAT2 (Morissette and Di Paolo, 1993b;
Walker et al., 2000; Bhatt and Dluzen, 2005; Ji et al., 2007; Dluzen
et al., 2008) and are less susceptible to NSDA toxins than males
(Miller et al., 1998; Bourque et al., 2011), the preservation of a
integral and optimal DA system seems to be important in the
neuroprotection process. In addition, DAT afﬁnity and density
were not modulated by 17β-estradiol treatment in male rodents
(Jourdain et al., 2005; Meyers and Kritzer, 2009) but protection
against MPTP is observed (Bourque et al., 2009). While it has
been suggested that inhibition of the DAT by estradiol could be
an important mechanism for neuroprotection in females (Dis-
shon and Dluzen, 1999), the ﬁndings that 17β-estradiol can be
effective as a neuroprotectant against MPTP in both males and
females, in the apparent absence of any effects upon the DAT in
males, suggests alternative or supplementary mechanisms for neu-
roprotection by this gonadal steroid hormone. As one possibility,
there may exist an important interaction among 17β-estradiol,
its binding with ERs and the DAT that contributes to this abil-
ity to display neuroprotection. Speciﬁcally, data resulting from
an in vitro study have demonstrated that a physiological con-
centration of 17β-estradiol does not change the membrane and
total DAT levels, whereas estrone and estriol cause removal of
membrane DAT, with a reduction of total cellular DAT content
also being observed with estriol (Alyea and Watson, 2009). Fur-
thermore, 17β-estradiol and estrone, but not estriol, differently
changed the subcellular localization of the ERs (Alyea and Wat-
son, 2009). Despite the reduction in membrane DAT caused by
estrone and estriol, estrone shows some weak protective activity
against MPTP whereas estriol lacks a neuroprotective effect (Jour-
dain et al., 2005) and these two estrogens are weak agonist of
ERs (Kuiper et al., 1997), supporting a close link between afﬁn-
ity for ER binding and a neuroprotective effect. Whereas DAT
knockout mice have shown an important role for the DAT in
MPTP and MA toxicities (Gainetdinov et al., 1997; Fumagalli
et al., 1998), the effect of 17β-estradiol in preserving the afﬁn-
ity and the density of the DAT seems to be an important aspect
of the neuroprotective effect. Furthermore, higher DAT density
has been reported in females than males (Morissette and Di Paolo,
1993b) and females are less affected by toxins than males (Bourque
et al., 2009). Clinical imaging studies in healthy participants have
shown that striatal DAT binding is higher in women than men
(Lavalaye et al., 2000; Staley et al., 2001) and a lower incidence
and prevalence of PD is observed in women. Studies in healthy
postmenopausal women reported that a 6-week period of estro-
gen therapy increases [99mTc]TRODAT-1 binding to DAT in the
anterior putamen (Gardiner et al., 2004), that long-term use of
estrogen therapy increases dopaminergic function (Craig et al.,
2004), and estrogen therapy has been associated with a decreased
risk of PD (Currie et al., 2004; Popat et al., 2005).
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An intriguing sex speciﬁc effect of estradiol is observed in
MA-treated male mice. While male rodents demonstrate a neuro-
protective action of 17β-estradiol in response to MPTP (Bourque
et al., 2009) a lack of any apparent beneﬁcial effect from estrogen
is seen in MA-treated mice (Dluzen et al., 2002). MPTP and MA
mechanisms of action differ markedly, with MPTP affecting the
mitochondrial complex 1 (Smeyne and Jackson-Lewis, 2005) and
MA producing excessive amounts of DA release likely leading to
reactive species production (Fleckenstein et al., 2007). The failure
of 17β-estradiol to function as a neuroprotectant against MA in
the male mouse is not readily obvious. A critical component of
MA toxicity is body temperature, which inﬂuences the oxidation
process (LaVoie and Hastings, 1999). MA itself produces hyper-
thermia and variations of body temperature have been reported to
inﬂuence the extent of degeneration (LaVoie and Hastings, 1999).
While female mice experience reductions of body temperature in
response to estradiol treatment (Gao and Dluzen, 2001b), this
effect was not present in male mice (Dluzen et al., 2002), where
no change in body temperature was observed. The differential
between female and male mice with regard estradiol’s effect on
body temperature could be involved in the sex difference response
to the toxin. Interestingly, MPTP or MPP+ also produce a brief
initial period of hyperthermia in mice, but this is followed by
a more prolonged period of hypothermia (Satoh et al., 1987).
Moreover, mice maintained at 4˚C show a greater accumulation
of striatal MPP+ along with greater depletions of striatal DA as
compared with mice maintained at 22˚C (Moy et al., 1998). Essen-
tially opposite results are obtained with MA, where greater striatal
DA concentration depletions are obtained in mice maintained at
22˚C (Moy et al., 1998) and hypothermia diminished MA-induced
striatal DA toxicity in the rat (Bowyer et al., 1992). Accordingly, the
inability for estradiol to decrease body temperature may represent
a particularly critical variable with regard to moderating MA-, but
not MPTP-, induced striatal DA toxicity in the male mouse.
A critical point to consider is whether developmental effects
of steroids (organizational effects) inﬂuence the neuroprotective
response against toxin observed in adults. Anderson et al. (2005)
attempted to address this issue of organizational effects in the MA
model. Brieﬂy, female mice gonadectomized at 3–5 days of age
and immediately treated with testosterone propionate (1.25mg),
that is, masculinized females, continued to show an estrogen neu-
roprotection response to MA when tested as adults. Male mice
gonadectomized at 3–5 days of age and immediately treated with
sesame oil, that is, feminizedmales, failed to show an estrogen neu-
roprotection response when tested as adults. Therefore, attempts
to masculinize female mice or feminize male mice did not alter
the sexually dimorphic effect of estrogen (i.e., neuroprotection in
females and no effect in males) upon MA-induced neurotoxicity
responses. These results suggest that the long-term and even orga-
nizational effects of steroids may not necessarily (or adversely)
affect the responses obtained in adults.
Estrogens receptors
The presence of 17β-estradiol within the brain at the time of
injury is a critical component of the neuroprotective effect of this
steroid since post-treatment fails to protect DA neurons (Gajjar
et al., 2003; Liu and Dluzen, 2006). The timing of 17β-estradiol
treatment also seems to inﬂuence the extent of this response since
different durations of treatmentproduce varyingdegrees of neuro-
protection (Gajjar et al., 2003), with increased effectiveness being
associated with a longer treatment intervals (24> 12> 0.5 h),
suggesting that different mechanisms of 17β-estradiol are operat-
ing. Estradiol produces its actions by genomic and non-genomic
effects. Genomicmechanisms involve gene transcriptionmediated
by activation of nuclear receptors, ERα and ERβ, and require peri-
ods of hours to days to exert their effects (Vasudevan and Pfaff,
2008). Non-genomic actions are deﬁned by rapid effects (within
minutes even seconds) of 17β-estradiol initiated by interaction
with membrane ER and/or G protein-coupled estrogen receptor 1
(GPER1), leading to activation of signaling pathways (Vasudevan
and Pfaff, 2008). Genomic and non-genomic actions of 17β-
estradiol are known to act together to potentiate transcriptional
activity (Vasudevan and Pfaff, 2008). 17β-estradiol can activate
Akt and extracellular signal-regulated kinase (ERK1/2) signaling;
both of which have been implicated in 17β-estradiol neuropro-
tective effects (Bryant et al., 2006; Raz et al., 2008). 17β-estradiol
action can promote the up-regulation of neurotrophic factors such
as brain-derived neurotrophic factor, the anti-apoptotic molecule
Bcl-2 and/or inhibition of pro-apoptotic proteins such as BADand
Bax (Kipp et al., 2006; Brann et al., 2007). Interactions with growth
factors, such as insulin-like growth factor 1, can also contribute to
the protective effects of estradiol (Garcia-Segura et al., 2010) since
these actions promote survival and have been implicated in the
neuroprotective effect of 17β-estradiol.
Non-genomic actions of 17β-estradiol show sex differences in
the activation of intracellular mechanisms in the mouse brain
(Abraham and Herbison, 2005). Moreover, a sex-related differ-
ence in ERK1/2 activation by 17β-estradiol is reported in male
and female rat astrocytes (Zhang et al., 2002b). Differential distri-
butions of ERs are reported between female andmale rodents. ERα
has been detected in the striatum of both female and male rodents
(Merchenthaler et al., 2004; Shughrue, 2004; Rodriguez-Navarro
et al., 2008; Schultz et al., 2009) whereas the levels of ERα, as quan-
tiﬁed by Western blot, are higher in the striatum of female mice
(Rodriguez-Navarro et al., 2008). Furthermore, ERα seems to be
primarily associated with the membrane fraction rather than the
nuclear part when extracted from homogenized striatal tissue of
female rats (Schultz et al., 2009). ERβ is not found in the striatum
of male mice but both presence and absence have been reported in
females (Mitra et al., 2003; Merchenthaler et al., 2004; Shughrue,
2004). Both ERα and ERβ are present in female mice substan-
tia nigra pars compacta and striatum (Mitra et al., 2003) but are
absent in male mice (Shughrue, 2004) whereas their presence has
been detected in male rats (Zhang et al., 2002a). In female mice,
the immunoreactivity of ERβ in substantia nigra pars compacta
seems to be more prominent than ERα whereas the opposite seems
true of the striatum (Mitra et al., 2003). GPER1 has been detected
in the striatum and substantia nigra pars compacta with a similar
pattern of distribution between female and male rodents (Brailoiu
et al., 2007; Hazell et al., 2009; Bourque et al., 2011). The litera-
ture seems to be more consistent concerning ERα showing only
species difference between male rats and mice in substantia nigra.
Frontiers in Endocrinology | Neuroendocrine Science September 2011 | Volume 2 | Article 35 | 10
Bourque et al. Sex steroids neuroprotection and neuromodulation
More discrepancies appear for the distribution of ERβ. Differences
in species, the antibody used and cellular localization (nuclear;
Mitra et al., 2003; Merchenthaler et al., 2004 versus extranuclear;
Mitra et al., 2003) could provide some explanation for the diver-
gent distribution of the ERβ described. Thus, when referring only
to studies with mice, a different distribution seems to be present
between females and males, as ERs are present in female mice sub-
stantia nigra pars compacta but absent in males. ERα has been
detected in the striatum of both female and male mice, whereas
the levels of this receptor seem higher in females. ERβ is not
found in the striatum of male mice but both presence and absence
have been reported in females. Colocalization of ERβ and tyrosine
hydroxylase in substantia nigra pars compacta has been observed
in both female and male rats (Creutz and Kritzer, 2004; Quesada
et al., 2007). Studies combining double-label immunocytochem-
istry for ERβ and tyrosine hydroxylase positive substantia nigra
pars compacta neurons with retrograde tract tracing revealed a
deﬁned topographical organization strongly favoring projection
to the ventral striatum, whereas few ERβ and tyrosine hydroxy-
lase positive substantia nigra pars compacta neurons were found
to project to the dorsal striatum (Creutz and Kritzer, 2004). No
androgen receptor and tyrosine hydroxylase positive substantia
nigra pars compacta neurons were found to project to the stria-
tum (Creutz and Kritzer, 2004). It seems reasonable to postulate
that the sex differences observed in the distribution and levels of
ERs could inﬂuence the dopaminergic system and mechanisms
of 17β-estradiol action. It remains to be investigated whether
estradiol activates the same signaling molecules in females and
males and/or if a sexual dimorphism in downstream signaling
proteins is linked with the ERs that are present in the dopaminer-
gic system. Neuroprotective effects of 17β-estradiol against toxins
can involve different signaling pathways between females and
males.
In vitro studies have shown that ERs subtypes (including
GPER1) have different effects in 17β-estradiol-mediated DA efﬂux
(Alyea et al., 2008) and that ERα and ERβ, but not GPER1, are
associated with the plasma membrane DAT (Alyea and Watson,
2009). Moreover, modulation of tyrosine hydroxylase transcrip-
tion by 17β-estradiol is regulated in opposite directions depending
on the ER subtype (Maharjan et al., 2005). Using ERα and ERβ
knockout male mice, our group and others have investigated
the role of each ER on NSDA markers in the neuroprotective
effect of 17β-estradiol against MPTP toxicity (Morissette et al.,
2007; Al-Sweidi et al., 2011). While ERα and ERβ knockout mice
show normal striatal DA concentrations, DAT speciﬁc binding
was increased in ERα knockout mice and normal VMAT2 spe-
ciﬁc binding was measured (Morissette et al., 2007; Al-Sweidi
et al., 2011). By contrast, ERβ knockout mice display lower DA
turnover as well as a reduction in striatal DAT and VMAT2 spe-
ciﬁc binding (Morissette et al., 2007;Al-Sweidi et al., 2011). Female
ERα knockout mice exhibit higher D1 DA receptor expression
levels and reduced expression of tyrosine hydroxylase and brain-
derived neurotrophic factor in the midbrain of both female and
male ERα knockout mice (Kuppers et al., 2008). Whereas both
ERα and ERβ male knockout mice display normal serum 17β-
estradiol levels, higher levels of testosterone, dihydrotestosterone,
and 3β-diol weremeasured in ERαmale knockoutmice (Al-Sweidi
et al., 2011). The highest susceptibility to MPTP was observed in
ERα male knockout mice and the levels of testosterone and 3β-
diol were inversely correlated with the loss of DA concentration
(Al-Sweidi et al., 2011). The signiﬁcance of these ﬁndings remains
to be elucidated, however it is interesting to note that not only
does testosterone fail to induce a neuroprotective effect in MPTP
and MA-treated mice (Dluzen, 1996; Ekue et al., 2002; Lewis and
Dluzen, 2008) but may exacerbate NSDA neurotoxicity responses
as described below in Section “Mechanism of Action of Andro-
gens in Female and Male Rodents.” Exogenous 17β-estradiol does
not protect ERα or ERβ male knockout mice from MPTP tox-
icity, showing that both ERs are necessary for neuroprotection
(Morissette et al., 2007; Al-Sweidi et al., 2011). Moreover, the lev-
els of ERs were not modulated by MPTP lesion (Shughrue, 2004).
In contrast, we have recently reported increased GPER1 levels in
male mice with a moderate MA-induced lesion, while the levels
of this receptor remains unchanged in MA-treated female mice
(Bourque et al., 2011). Thus, the sex difference in ERs distrib-
ution as well as the different roles for each of the ERs in the
DA system could be associated with the sex differences present
in the susceptibility to toxin and also inﬂuence their responses to
17β-estradiol.
MECHANISM OF ACTION OF ANDROGENS IN FEMALE AND MALE
RODENTS
In contrast to that of estradiol, there exists relatively little informa-
tion on the mechanisms of testosterone action within the NSDA
system as related to striatal DA toxicity. To a large extent this
disinterest stems from the apparent absence of any neuroprotec-
tant effects of this gonadal steroid. However, with the advent of
data suggesting that this male gonadal steroid may contribute to
an aggravation of toxins that target the NSDA system (Gao and
Dluzen, 2001a; Dluzen et al., 2002; Murray et al., 2003; Gillies
et al., 2004; Lewis and Dluzen, 2008), it might be worthwhile to
re-consider these testosterone effects and mechanisms.
With regard to the NSDA system, treatment of male rats with
the anabolic-androgen steroid, nandrolone decanoate, leads to
decreases in D1-like receptor labeling and an increase in D2-like
binding sites within the caudate putamen (Kindlundh et al., 2001),
which creates a type of hypodopaminergic condition. Moreover,
a reduction in locomotor behavior and rearing are also observed
in these rats treated with nandrolone decanoate (Johansson et al.,
2000). Further support for this attenuation in striatal dopamin-
ergic function by testosterone is provided from data showing
that spontaneous (Dluzen and Ramirez, 1989) and amphetamine-
stimulated locomotor and stereotyped behaviors (Menniti and
Baum, 1981; Savageau and Beatty, 1981; Beatty et al., 1982; Dluzen
et al., 1986) are decreased in the presence of testosterone. More-
over, basal (Dluzen and Ramirez, 1989) and stimulated (Her-
nandez et al., 1994; Shemisa et al., 2006) striatal DA release are
decreased in testosterone treated rodents. Collating these parame-
ters leads to the conclusion that the presence of testosterone is
associated with a generalized reduction in NSDA activity, like that
seen in PD.
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The exact mechanisms involved in producing this testosterone-
dependent reduction in NSDA function are not know, but some
tangential data are available that can provide some perspective.
Testosterone treatment of neuroblastoma cells induces apopto-
sis through activation of a Ca2+ signaling pathway, an effect
that cannot be attributable to conversion into estrogens (Estrada
et al., 2006). With the use of N27 cells, which might represent a
more relevant model for testing toxicity on dopaminergic neu-
rons, it was also demonstrated that testosterone contributes to an
apoptotic cascade, impairing mitochondrial function and increas-
ing oxidative stress to produce a caspase-3-dependent cleavage
which would activate protein kinase Cδ (Cunningham et al.,
2009). Additional work with this model revealed that this testos-
terone effect involved an intracellular androgen receptor and was
not attributable to conversion into estradiol. The fact that, at
least in the rat, androgen receptors are mainly expressed in the
substantia nigra pars compacta versus the substantia nigra pars
reticulata (Kritzer, 1997), combined with data from the cortex of
the mouse that androgen receptors show increased phosphory-
lation levels to testosterone in aged males (Thakur et al., 2000),
provides particularly relevant implications regarding the capac-
ity for testosterone to exert age-related, adverse consequences
within the NSDA system as related to PD. This testosterone-
dependent increase in oxidative stress and free radical production
may, in part, result from modulation of VMAT2 function by
this gonadal steroid. Signiﬁcantly greater amounts of reserpine-
evoked DA release are obtained from the striatum of orchidec-
tomized mice treated with testosterone versus those not receiv-
ing testosterone (Shemisa et al., 2006). Such results suggest that
testosterone may be working like and/or synergistically with reser-
pine to inhibit VMAT2 function, thereby producing excessive
DA levels available for metabolism to free radicals. Testosterone
produced a non-signiﬁcant decrease in vesicular DA uptake in
cocaine-treated orchidectomized rats (Chen et al., 2003), and
the VMAT2 of males is more sensitive to the toxic effects of
MA, as substantia nigra VMAT2 mRNA is signiﬁcantly decreased
in male, but not female, mice receiving either low (20mg/kg)
or high (40mg/kg) doses of this NSDA toxin (Bourque et al.,
2011).
Taken together, the capacity for testosterone to induce a gen-
eralized hypodopaminergic state combined with an age-related
enhanced potential for oxidative stress in critical NSDA sites, sug-
gests a role and mechanism for this gonadal steroid in PD. In this
way, the sex difference in the incidence of PD may involve a com-
bination of neuroprotective effects of estrogens within women
and neurodestructive effects of testosterone in men. While much
work remains to be performed on this topic, these bidirectional
sex and hormonal responses to NSDA toxins may comprise a
rewarding direction of investigation to understand the pathology
of conditions like PD.
CONCLUSION
Clinical and epidemiological reports on PD aswell as animalmod-
els show a sex difference in neurodegeneration of the NSDA sys-
tem. Most of the experimental studies focused on a 17β-estradiol
neuroprotective effect, showing that low doses, but not high doses,
are effective to protect the NSDA pathway against toxins. Fur-
thermore, increased effectiveness of 17β-estradiol is associated
with a longer treatment interval. While having received less atten-
tion, progesterone shows interesting neuroprotective actions in
both male and female mice and does not oppose the effect of
17β-estradiol on the NSDA system when these two steroids were
co-administered. Androgens lack neuroprotective properties in
NSDA pathway and may even worsen the extent of the lesion.
Genomic and non-genomic actions of 17β-estradiol are impli-
cated in neuroprotection of NSDA system and the presence of
both ERα and ERβ are critical for a beneﬁcial effect. The contri-
bution of GPER1 in the neuroprotective effect of 17β-estradiol in
the NSDA pathway remains to be investigated but recent in vitro
(Gingerich et al., 2010) and in vivo (Lebesgue et al., 2010) studies
have reported a neuroprotective action of GPER1 activation.
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